Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07576725). This is a study registration, not published results. Lead sponsor: Fred Hutchinson Cancer Center. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 50 participants (ESTIMATED). Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Hodgkin Lymphoma, Kaposi Sarcoma, Metastatic Acral Lentiginous Melanoma, Metastatic Basal Cell Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Merkel Cell Carcinoma, Metastatic Mucosal Melanoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Basal Cell Carcinoma, Unresectable Cervical Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Cutaneous Melanoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Merkel Cell Carcinoma, Unresectable Mucosal Melanoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Urothelial Carcinoma. Interventions: PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; PROCEDURE: Magnetic Resonance Imaging; BIOLOGICAL: Nivolumab. Primary outcome measures: Objective response , Up to 4 years after completion of study treatment. Brief summary: This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nivolumab is a type of immune checkpoint inhibitor (ICI). ICIs have revolutionized the treatment of numerous cancers with remarkable improvement in participant outcomes. However, accessibility of ICIs is extremely poor on a global scale, mainly due to high costs. Previous research has suggested that these drugs can be given at lower doses and reduced frequency than their approved dosing regimens, with similar results. Giving nivolumab at a lower dose and less often may help reduce the cost of therapy, improve immunotherapy accessibility, and therefore improve survival outcomes globally.